CREATE Medicines Raises $122M Series B to Push In Vivo CAR Therapy Into the Biotech Mainstream

CREATE Medicines just raised $122M in Series B funding led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and existing backers. The Cambridge-based biotechnology company is building in vivo immune programming therapies designed to engineer immune cells directly inside the body using mRNA-LNP delivery systems.

That sentence alone lands differently if you understand how much friction still exists inside modern cell therapy. CREATE Medicines is not trying to make incremental improvements to the current CAR-T manufacturing model. The company is attacking the industrial logic underneath it. Traditional ex vivo cell therapy often resembles a luxury supply chain duct-taped to a moonshot science project. Extraordinary clinical outcomes. Brutal scalability. Long timelines. Complex manufacturing. Eye-watering costs. Everybody loves the science until the invoice shows up wearing brass knuckles.

The broader implication is larger than one funding round. Investors are increasingly backing platforms capable of compressing development timelines, reducing manufacturing complexity, and widening patient access simultaneously. In biotech right now, speed is no longer a feature. Speed is capital formation.

What Happened

CREATE Medicines announced a $122M Series B financing to accelerate development of its in vivo CAR pipeline across oncology and autoimmune disease. The company focuses on programming immune cells directly inside the patient using RNA-powered therapies delivered through lipid nanoparticles, commonly known as mRNA-LNP systems.

The financing round was co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners. Alexandria Venture Investments also participated alongside existing investors. CREATE Medicines CEO and cofounder Daniel Getts, PhD, has positioned the company around a core belief that the next phase of cell therapy will not be constrained by individualized manufacturing models.

The company’s platform aims to eliminate portions of the ex vivo process by engineering immune cells inside the body rather than extracting, modifying, and reinfusing them externally. That distinction matters more than biotech marketing departments would like to admit. The current CAR-T ecosystem produces remarkable therapies, but operationally, parts of the industry still resemble a Formula 1 car being serviced through airport security.

Why CREATE Medicines Matters

CREATE Medicines operates at the intersection of several major biotech trends: mRNA therapeutics, lipid nanoparticle delivery systems, in vivo gene programming, oncology, and autoimmune disease treatment. The company says it has treated more than 50 patients across 2 clinical trials and generated one of the largest datasets in the emerging in vivo CAR category.

CREATE Medicines also reported that MT-302 produced the first documented response using an in vivo CAR approach in solid tumors. That is the type of milestone competitors read twice. The deeper strategic value sits inside manufacturing economics and scalability. Ex vivo cell therapy remains expensive because every patient effectively becomes a custom production workflow.

CREATE Medicines is pursuing a model where therapies behave more like repeatable pharmaceutical infrastructure instead of individualized biological craftsmanship. Biology is difficult enough already. Adding artisanal logistics on top of it tends to make investors age in dog years.

Market Context

The CREATE Medicines funding round arrives during a broader recalibration inside biotech and venture capital. Investors are showing increasing preference for platforms capable of supporting multiple therapeutic programs while improving operational efficiency.

RNA-based therapies gained mainstream credibility following the COVID-19 vaccine cycle, but the next phase of the market is moving beyond vaccines into programmable medicine. Companies across the ecosystem are racing toward in vivo delivery models capable of transforming how gene and cell therapies are manufactured and administered.

CREATE Medicines joins a growing category of biotechnology companies attempting to industrialize advanced therapies without sacrificing efficacy. The challenge is enormous because biology rarely cooperates with PowerPoint optimism. Still, the market incentives are obvious.

Cancer affects millions globally each year. Autoimmune diseases impact hundreds of millions more. Existing cell therapies can produce extraordinary outcomes, but cost and complexity continue limiting access. Any company capable of reducing manufacturing friction while preserving clinical potency immediately becomes strategically important. That is why experienced investors continue writing large checks into this category despite broader venture caution.

Competitive Landscape

CREATE Medicines enters an increasingly crowded but highly consequential race involving in vivo CAR therapies, RNA delivery systems, and programmable immune engineering. The company differentiates itself through repeat-dose capability, targeted lipid nanoparticle delivery, non-viral engineering approaches, and its RetroT all-RNA gene-writing platform.

CREATE Medicines says the platform supports programming across T cells, NK cells, and myeloid cells without relying on traditional viral-vector infrastructure. That technical positioning matters because viral manufacturing remains one of the industry's recurring operational headaches. Expensive. Slow. Capacity constrained. The biotech equivalent of trying to run cloud infrastructure on fax machines and prayer.

Leadership also plays a meaningful role here. CREATE Medicines’ executive team includes Daniel Getts, Allan L. Shaw, Robert Hofmeister, Matthew Maurer, and Curtis Demick. The company’s scientific roots trace back to Myeloid Therapeutics and include associations with figures like Ronald Vale and Siddhartha Mukherjee. Those names carry weight because sophisticated biotech investors increasingly back teams, not just platforms.

What This Signals

The CREATE Medicines Series B signals that venture firms still have strong appetite for biotechnology companies capable of reshaping therapy economics, not merely improving outcomes incrementally. The funding environment for biotech remains selective. Capital is still available for companies with credible science, differentiated platforms, and operational clarity.

What disappeared was investor patience for vague narratives wrapped in expensive conference booths. CREATE Medicines sits inside a category where scientific ambition intersects directly with healthcare infrastructure. If in vivo immune programming succeeds at scale, it could materially change manufacturing requirements, treatment accessibility, and cost structures across oncology and autoimmune disease markets.

That possibility explains why investors continue treating this segment as strategic infrastructure rather than speculative science fiction.

Frequently Asked Questions

What is CREATE Medicines?

CREATE Medicines is a Cambridge, Massachusetts-based biotechnology company developing in vivo immune programming therapies using mRNA-LNP delivery systems for oncology and autoimmune diseases.

How much funding did CREATE Medicines raise?

CREATE Medicines raised $122M in Series B funding led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners.

What does CREATE Medicines develop?

CREATE Medicines develops in vivo CAR therapies and RNA-powered immune programming technologies designed to engineer immune cells directly inside the body.

Who leads CREATE Medicines?

CREATE Medicines is led by CEO and cofounder Daniel Getts, PhD. The executive team also includes Allan L. Shaw, Robert Hofmeister, Matthew Maurer, and Curtis Demick.

Why is in vivo CAR therapy important?

In vivo CAR therapy aims to reduce the manufacturing complexity and cost associated with traditional ex vivo cell therapies by programming immune cells directly inside patients.

What does the CREATE Medicines funding round signal about biotech markets?

The funding round reflects continued investor interest in scalable biotechnology platforms capable of improving manufacturing efficiency, reducing costs, and expanding access to advanced therapies.